Tenofovir diphosphate intracellular concentration following tenofovir alafenamide administration in bictegravir‐containing vs . dolutegravir‐containing antiretroviral regimens
British Journal of Clinical Pharmacology · 30.10.2026
DOI: 10.1002/bcp.70881 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.10.2026. Verfasst von Micol Ferrara und 10 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GILEAD Sciences.
Abstract (Originalsprache)
This study investigates intracellular (IC) exposure of tenofovir alafenamide (TAF) and its clinical determinants in experienced people living with HIV. We conducted a monocentric retrospective analysis of 86 adults treated with either bictegravir (BIC)‐ or dolutegravir (DTG)‐containing regimen. Plasma and IC trough concentrations (C trough ) of tenofovir diphosphate (TFV‐DP) were examined in relation to demographic and renal parameters. A significant correlation emerged between plasma and IC TFV‐DP C trough . Higher plasma TFV levels were associated with older age and reduced estimated glomerular filtration rate. Adherence calculated as proportion of days covered (PDC) did not differ between regimens. These findings provide novel real‐world insights into IC TFV‐DP pharmacokinetics and suggest that BIC‐containing regimens may enhance IC drug accumulation, although the impact of this observation on virological outcomes requires further studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.
- Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
- Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Turin, Italy.
ORCID-Profile: Micol Ferrara, Antonio D'Avolio
Förderung
- GILEAD Sciences
Zitieren
APA
Ferrara, M., Maccario, V., Fantino, S., Clemente, E., Barrera, F., Palermiti, A., Soloperto, S., De Nicolo, A., D'Avolio, A., Di Perri, G., & Bonora, S. (2026). Tenofovir diphosphate intracellular concentration following tenofovir alafenamide administration in bictegravir‐containing vs . dolutegravir‐containing antiretroviral regimens. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70881
Vancouver
Ferrara M, Maccario V, Fantino S, Clemente E, Barrera F, Palermiti A, et al. Tenofovir diphosphate intracellular concentration following tenofovir alafenamide administration in bictegravir‐containing vs . dolutegravir‐containing antiretroviral regimens. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70881
BibTeX
@article{Ferrara2026,
author = {Ferrara, Micol and Maccario, Viviana and Fantino, Silvia and Clemente, Erica and Barrera, Federica and Palermiti, Alice and Soloperto, Sara and De Nicolo, Amedeo and D'Avolio, Antonio and Di Perri, Giovanni and Bonora, Stefano},
title = {Tenofovir diphosphate intracellular concentration following tenofovir alafenamide administration in bictegravir‐containing vs . dolutegravir‐containing antiretroviral regimens},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70881}
}
EUVIMED